• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
news type
Deccan Herald logo
In the media
8 Jul 2026

How Scientists Can Revive Global Health Drug Development

Deccan Herald
Press Releases Translations
8 Jul 2026

Brasil, Malásia e Tailândia estão prestes a iniciar ensaio clínico para testar tratamento promissor contra a dengue desenvolvido pelo Instituto Serum da Índia

Press Releases Translations
8 Jul 2026

Brasil, Malasia y Tailandia están a punto de iniciar ensayos clínicos para probar un prometedor tratamiento contra el dengue desarrollado por el Serum Institute of India

Press releases
8 Jul 2026

Brazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment developed by Serum Institute of India

Press Releases Translations
8 Jul 2026

ไทย บราซิล และ มาเลเซีย เตรียมเริ่มการศึกษาวิจัยทางคลินิก เพื่อทดสอบยารักษาไข้เลือดออกชนิดใหม่ที่พัฒนาโดยสถาบันเซรุ่มแห่งอินเดีย

Scientific articles
7 Jul 2026

Integrating molecular similarity and alphafold-based structural alignment for target discovery in trypanosoma cruzi

Pharmaceuticals
Patricia, 44, from Area 44 in Lilongwe, Malawi, has lived with vision loss for 10 years following a late diagnosis of cryptococcal meningitis.
Stories
30 Jun 2026

Cryptococcal meningitis: Africa’s neglected HIV killer

Woman in a field smiling
Publications
30 Jun 2026

2025 DNDi Financial Report

Publications
29 Jun 2026

Advancing global health innovation through Europe-Africa collaboration

News
29 Jun 2026

Eric Easom, Dr Marcus Lacerda, and Mathieu Lamiaux join the DNDi Board of Directors 

Scientific articles
22 Jun 2026

What Is in a Structure? Cell Permeability and Solubility of Series of Macrocycles and Linear Matched Pairs

Journal of Medicinal Chemistry
The Economist logo
In the media
25 Jun 2026

Ebola has put Africa’s fragile health systems in the spotlight

The Economist
Scientific articles
24 Jun 2026

Inspiring, shaping and sustaining an African research & development agenda

Nature Medicine
BFM logo
In the media
22 Jun 2026

What Malaysia Needs To Step Up In Dengue Management

BFM
Statements
22 Jun 2026

Open letter: Ensuring public return on public investment – Support for access planning and socially responsible innovation provisions in Framework Programme 10 (FP10)

Press releases
22 Jun 2026

More than 50 organizations urge MEPs to back access provisions in the EU’s next research programme

Page1 Page2 Page3 Page4 Page5
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license